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Event related brain potentials (ERPs)The objective of this study was to investigate the relation between growth hormone (GH) and attentional
electro-cortical responses to task-relevant stimuli (N2b), target detections, speed of responding, P300
latencies, and performance on neuropsychological tests in 19 patients who received external beam radiation
therapy for brain tumors in adulthood. In addition, we studied the association between IGF-I and activation of
the motor cortex responses (lateralized readiness potential, LRP).
Brain function was assessed using event-related potentials (ERPs) during a go/no go selective-attention task,
including N2b, P300 and selective motor preparation as reﬂected in the LRP. Correlations were calculated
between peak GH levels after a standardized growth hormone-releasing hormone (GHRH)–arginine test,
plasma IGF-I, and cognitive functions. We separately studied four patients who were diagnosed with GHD
according to the GHRH–arginine test.
Performance on WAIS digit span backward and the Rey–Osterrieth complex ﬁgure test correlated positively
with GH peak. GHD patients performed worse than non-GHD patients on Stroop interference, trail making
B/A attentional shifting and Rey–Osterrieth complex ﬁgure test. At trend-level signiﬁcance, trails A perfor-
mance was better in patients with lower GH levels and higher radiation doses, and GHD participants detected
fewer targets in the go/no go selective attention task. N2b was not signiﬁcantly altered by GH status. Further-
more, plasma IGF-I was positively correlated with the sum of digit span forward and backward. No relations
with P300 were observed.
In this study only 21% (4/19) of the patients who received fractionated radiotherapy for a non-endocrine
brain tumor were diagnosed with GHD. GHD in these patients was associated with impaired interference
control, attentional shifting, and visual long-termmemory. The results for interference control and attentional
shifting suggest an additional effect of the radiation history.
© 2012 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Growth hormone (GH) deﬁciency (GHD) has often been associated
with impaired psychological functions, and evidence is also emerging
that a relationship exists between the GH-insulin-like growth factor-I
(IGF-I) axis and cognitive function [1]. Although reduced GH secretion
may directly affect cognitive function, it is also likely that subsequent
attenuation of systemic or local IGF-I levels may be responsible for the
observed effects [1,2].ental Psychology and Psycho-
m 16.21 3584 CS Utrecht, The
511.
vier OA license.A review and meta-analysis indicated that neuropsychological
performance was impaired in adult GHD patients, predominantly in
the domains of memory and executive functions, and that moderate
improvements during GH therapy were found in particular also for
these domains [2,3]. Studies of event related brain potentials (ERPs)
offer support for underlying pathophysiological mechanisms. P300
latencies were found to be signiﬁcantly prolonged in GHD patients
and were signiﬁcantly shortened after 6 months of GH therapy [4,5].
Furthermore, Lijfﬁjt et al. [6] demonstrated reduced attention-related
electro-cortical responses (N2b) to task-relevant stimuli in adults
with childhood-onset GHD, which may reﬂect functional deﬁcits in
the cingulate cortex [7]. Previous research showed that the lateralized
readiness potential (LRP), an ERP index for selective motor preparation,
was smaller in elderly men with low IGF-I levels, indicating that both
GH and IGF-I may contribute to the physiology of cognitive function [8].
43E.H. Quik et al. / Growth Hormone & IGF Research 22 (2012) 42–47Long-term cognitive impairment is highly prevalent and burden-
some in patients with brain tumors, possibly as a consequence of
irradiation. However, adult patients with a low-grade glioma or
meningioma who had been irradiated showed no additional detri-
mental effect by irradiation over damage by the tumor and by neuro-
surgery [9]. Shukitt-Hale et al. [10] found that cranial irradiation
was associated with reduced performance in tasks assessing spatial
learning and memory, which could at least partly be due to a lack of
GH [11]. In the present study we report measures of cognitive func-
tioning in relation to GH secretion, assessed by GH secretory capacity
after GH releasing hormone (GHRH)–arginine, in patients who had
previously undergone cranial irradiation for neurological tumors.
Our hypothesis was that low GH secretion would be associated with
reduced attentional electro-cortical responses to task-relevant
stimuli (N2b), reduced accuracy of performance, slower speed of
responding, increased P300 latencies, and impaired performance
on neuropsychological tests of memory. For IGF-I we speciﬁcally
predict an association with selective motor preparation (LRP) and
speed of responding (reaction time). An additional comparison
was made between patients with and without GHD, with respect
to the measures mentioned previously.
2. Materials and methods
2.1. Subjects
We studied 19 patients (mean age 43.3 years, SD 10.6, range
30–69 years; 8 females; Table 1) who had received therapeutic crani-
al irradiation for primary brain tumors in adulthood. GH secretion
was assessed using a standard GHRH–arginine test. Other pituitary
hormones (cortisol, thyroid hormone, gonadal hormones) were ei-
ther normal or had to be adequately substituted for at least 3 months.
Four participants (mean age 49.3 years, SD 14.2, range 36–69 years; 1
female) who had a GH peaks lower than 9 μg/l after GHRH–arginine
stimulation were diagnosed as GH deﬁcient [12]. The other 15 partic-
ipants (mean age 41.7 years, SD 9.3, range 30–62; 7 females) had an
adequate GH response. We excluded participants with other neuro-
logical or psychiatric disease, other endocrine or internal disease,
severe obesity (BMI>32 kg/m2), malnutrition (BMIb18.5 kg/m2),
chronic alcohol or drug abuse, and use of medication that may affect
cognitive functioning. There were no differences in radiation dose
or tumor characteristics between GHD and non-GHD subjects. As
expected, the GHD subjects had higher outcome measures of central
obesity (BMI 27.7±1.8 vs. 24.7±2.5 kg/m2, pb .05; waist 104.8±
6.9 vs. 86.4±8.1 cm, pb .01).
The local medical ethics committee approved the study protocol.
The study was approved by our local ethics committee, and con-
formed to The Code of Ethics of the World Medical Association
(Declaration of Helsinki), printed in the British Medical Journal
(18 July 1964). All subjects gave written informed consent.
2.2. Procedure
The GHRH–arginine test, which was performed according to stan-
dard procedures [12], took place in the morning. GHRH was obtained
from Ferring (100 μg, Ferring Pharmaceuticals, The Netherlands). GH
was measured using an immunometric technique on an Immulite
Analyzer (Diagnostic Products, Los Angeles, CA). One microgram per
liter corresponds to 2.6 mIU/l (WHO International Ref. Prep 80/505).
IGF-I was measured using an immunometric technique on an Ad-
vantage Chemiluminescense System (Nichols Institute Diagnostics,
San Juan Capistrano, CA).
In the afternoon of the same day, the ERP task (N2b, P300) and
the neuropsychological tests were performed. All these tests were
performed individually and under identical circumstances, in a
sound-attenuated room.2.3. Tasks
Standardized neuropsychological tests used were WAIS III digit
span subtest, 15 word test, Rey–Osterrieth complex ﬁgure test, Stroop
color–word task, trail making test A&B, Brixton spatial anticipation
task, WAIS III symbol substitution subtest, WAIS III similarities
subtest, verbal ﬂuency N, A and animals and the Dutch adult reading
test (Table 2). For detailed descriptions, the reader is referred to Nel-
son [13], Lezak [14], Aleman et al. [15], and Ball et al. [16]. Typical
neuropsychological methods to assess selective attention are the
Stroop color–word task (resistance against interference from distract-
ing information), and the trail making task (shifting selective atten-
tion from one category to the other). ERPs were recorded during a
go/no go selective-attention or ‘selection-potential’ task, as we
have described previously [6,17].
2.4. Statistics
Bivariate Pearson correlations were calculated (two-tailed) using
an SPSS® 12.0.1 for Windows between the peak GH level during
the GHRH–arginine test, plasma IGF-I and all cognition outcome
parameters (neuropsychological tests and ERP data). Furthermore,
GHD-subjects were compared with non-GHD-subjects using an
ANOVA.
3. Results
3.1. GH secretion and IGF-I
Mean peak GH in all subjects (Table 1) was 26.9 μg (range 2.4–
96.2; SD 23.0), in the 4 GHD subjects 5.5 μg/l (range 2.4–8.1, SD 2.5)
and in the non-GHD subjects 32.6 μg/l (range 9.6–96.2, SD 22.7).
Mean plasma IGF-I levels for GHD and non-GHD subjects were re-
spectively 134.3 (range 126–141, SD 6.7 ) and 130.8 ng/ml (range
93–206, SD 30.5). No signiﬁcant correlation was found between GH
peak and IGF-I.
3.2. Radiation
The mean radiation dose of all 19 patients was 55.1 Gy (range
45–60; SD 5.0). Patients received radiotherapy in daily fractions of
1.8 to 2.0 Gy. Except for two patients (Table 1, patient 9 and 14),
the pituitary gland and hypothalamus could be fully shielded from
the high dose planning target volume. Particularly in the patients
with GHD, these endocrine organs at risk did not receive more than
30% (15–20 Gy) of the prescribed dose. The dose of total radiation
did not differ between the GHD group (mean 58.3 Gy, range 54–60)
and the non-GHD groups (mean 54.3 Gy, range 45–60). No signiﬁcant
correlations between radiation dose and GH peak were found
(p=.16).
3.3. Neuropsychological tests
The 4 GHD patients performed signiﬁcantly worse than non-GHD
patients in all Stroop-test conditions (Fig. 1). Although, when
separately analyzed, GHD and non-GHD subjects did not perform
differently on trail making A (time in seconds needed to connect
numbers) and trail making B (attentional shifting), a signiﬁcant
difference in trail making B/A ratio between the two groups was
found (p=.04; Fig. 2). In addition, a positive trend-level correlation
between trail making A score and GH peak (r=.40, p=.09) was
observed. GHD subjects performed worse on the Rey–Osterrieth
complex ﬁgure memory test, (as revealed by the ratio score, p=.01,
Fig. 3a) and GH peak was positively correlated with the ratio score
(pb .01; Fig. 3b). Furthermore, GH peak positively correlated with
the WAIS III digit span backwards (r=.46, pb .05; data not shown).
Table 1
Characterization of individual patients. (To be published on journal website.)
Patient
No.
Age
(years)
Sex
M/F
BMI
kg/m2
Waist
(cm)
Diagnosis Tumor localization Radiation dose
(Gray)
Radiation interval
(months)
GH peak
(μg/l)
IGF-I
(μg/l)
1 36 M 25.5 112 Astrocytoma grade II Right postcentral 60 91 2.4 126
2 43 M 27.5 97 Anaplastic mixed glioma Left frontal 59 86 4.6 132
3 57 F 29.8 109 Meningioma Left orbital/frontal lobe 54 50 6.9 138
4 49 M 27.8 101 Astrocytoma grade IV Left frontal 60 68 8.1 141
5 32 F 27 83 Anaplastic oligo-astrocytoma Temporo-occipital 60 28 9.6 145
6 35 M 26.3 99 Medulloblastoma Left cerebellar 54 87 11.9 114
7 39 M 25.8 91 pinealoblastoma Pineal gland 54 84 12.3 99
8 34 M 23.9 95 Germinoma Pineal gland 45 51 13.8 165
9 62 M 27.4 92 Meningioma Right cavernous sinus 54 16 23.5 105
10 41 F 29 86 Astrocytoma grade II Left parieto-occipital 60 59 24.6 125
11 48 M 23.4 94 Astrocytoma n.o.s. Right parietal 54 11 25 107
12 49 F 25.9 85 Astrocytoma n.o.s. Right frontoparietal 60 87 25 116
13 46 F 25.1 92 Medulloblastoma Cerebellum 54 45 26.2 206
14 42 F 25.8 81 Optic glioma Left para/suprasellar with infrasellar extension 50 32 29.6 134
15 42 M 21.9 86 Oligodendroglioma grade II Right frontoparasagittal 45 117 35.8 93
16 30 M 22.6 85 Astrocytoma grade IV Posterior 60 98 46.2 133
17 62 F 26.0 68 Meningioma Left frontotemporal 50 87 53.8 115
18 34 M 21.9 85 Medulloblastoma Posterior fossa 54 68 55 170
19 34 F 20.2 74 Astrocytoma grade III Left frontal 60 61 96.2 135
IGF-I reference levels: 30–35 years 90–275 (M), 92–280 (F); 36–40 years 85–250 (M), 85–260 (F); 41–50 years 74–220 (M), 75–220 (F); 51–60 years 64–200 (M), 65–200 (F); 61–
70 years 58–175 (M), 60–170 (F).
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ward and backward of the WAIS III (r=.51, p=.03; data not shown).
As to the other neuropsychological tests (Table 2), all other calcu-
lated differences between GHD and non-GHD patients as well as cor-
relations between GH peak and test outcomes were not signiﬁcant.
3.4. Selection potential task performance and ERPs
Mean target reaction time (MRT) was 433.4 ms (range 355.8–
500.8, SD 39.6). Mean percentage targets detected was 98.6%.
GHD participants detected somewhat fewer targets (p=.06). N2b
amplitude was somewhat smaller for GHD patients, but this differ-
ence was not signiﬁcant (data not shown). Mean reaction time
(speed of responding) and P300 did not differ signiﬁcantly between
the GHD and the non-GHD group. (Fig. 4).
GH peak was not signiﬁcantly correlated with percentage target
detections, nor with correct rejections. Speed of responding (mean
reaction time) on irrelevant trials, on which no response was wanted,
correlated with GH peak (r=.64, p=.05, data not shown). No signif-
icant correlation was found between GH secretion and N2b. Selective
motor preparation (LRP) was signiﬁcantly correlated to IGF-I (r=
−.51, p=.03). N2b was somewhat more negative when IGF-I levels
were higher, but the correlation was not signiﬁcant (r=−.39,Fig. 1. Mean (±SD) performance in three Stroop-task conditions (GHD vs. non-GHD subje
minus color).p=.095). Plasma IGF-I did not correlate with percentage target de-
tections, correct rejections nor with speed of responding.
4. Discussion
The present study has focused on pituitary function, with empha-
sis on GH secretion, in adults who had previously been irradiated
during adulthood for intracranial tumors and on the relation between
GH secretion and cognition. In particular, the focus was on the
correlation between GH secretion and the performance on a variety
of neuropsychological tests changes in GH secretion in relation to
neurophysiological changes assessed by ERP.
The two main ﬁndings of this study are, ﬁrst, that GHD was rela-
tively rare (21% (4/19)) and secondly, that GHD in these patients
was associated with an additional impaired cognitive functioning.
Only few studies have focused on pituitary function after cranial
irradiation for non-pituitary tumors during adulthood. In a very
recent meta-analysis by Appelman-Dijkstra et al. [18], only eight
studies (published between 1976 and 2006) were included with
265 adults following brain irradiation for intracerebral tumors. In
only four of these studies, the somatotropic axis was evaluated with
different tests, mostly after irradiation and in one study also after
surgery alone. The four studies show a prevalence of GHD aftercts). The rightmost part depicts the differences in the interference score (color–word
Fig. 2. Mean (±SD) performance on ratio score (TMT B/A).
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ulation was comparable with the 56 patients studied by Agha et al.
[19] who reported 32% of their patients having GHD. The difference
may be explained by different use of GH stimulation tests (they
used the insulin tolerance test (ITT) or a glucagon–arginine test).
The difference in outcome shows the dilemmas about GH testing in
these patients, and although hypothalamic damage may have
occurred, the ITT is often contraindicated because patients with a
history of brain tumors also often have a history of seizures. Darzy
et al. [20] performed both an ITT and a GHRH–arginine test in 49
adults who had been irradiated mostly during childhood, and
reported a signiﬁcant correlation between the outcome of both
tests, but a higher frequency of GHD when the ITT was used. How-
ever, it should be noted that for the diagnosis of isolated GHD, a
second GH stimulation test is required, and the GHRH–arginine
test is one of the best validated tests in patients with pituitary dis-
eases [12]. Popovic et al. used the ITT and the GHRH-GH releasing
peptide-6 test in a group of 22 adults who had been irradiated
either during childhood or adulthood, and reported a defective GH
releasable pool in 50% of their subjects, who were qualiﬁed as
GHD by either of the tests [11]. When we analyze our data in this
context, we feel that the four patients in our study who were diag-
nosed with GHD certainly qualify for this diagnosis, and should be
offered GH substitution therapy, while patients with GH peak levels
between 9 and 16.5 μg/l should be retested within a few years or
if symptomatic.
A signiﬁcant difference was found between the GHD and non-GHD
group for delayed visual memory as assessed by the Rey–Osterrieth
complex ﬁgure performance. This ﬁnding of an impaired delayed vi-
sual memory in GHD is consistent with that of an earlier report byFig. 3. Mean (±SD) ratio scores (delayed/immediate recall score) for the Rey–Osterrieth co
GH peak and the ratio score (b).Baum et al. [21]. In addition, we could demonstrate that a positive
correlation exists between delayed visual memory and the GH peak
in our entire study population, which may correspond with the
presence of GH receptors in the hippocampus, and ﬁts with previous
studies reporting a general relation between GH and memory [3].
Signiﬁcant differences were also found for several Stroop-task vari-
ables, the most important one being the color and word minus color
difference score, which reﬂects the inverse of interference control,
and indicates that GHD patients on average experienced more inter-
ference from incongruent color words when naming colors. In previ-
ous studies on childhood-onset GHD [22], no signiﬁcant impairment
in Stroop-interference control was observed and GH suppletion stud-
ies did not reveal effects on Stroop interference control [21]. In addi-
tion, the GHD patients in our study on average needed more time for
trail making B, relative to A, while there was no correlation between
trail making B performance and GH peak when we included the
non-GHD subjects. As with Stroop interference, the previous study
on childhood-onset GHD did not ﬁnd any differences in trail making
B attentional shifting [22], and GH therapy studies have failed to
show beneﬁcial effects on this variable [21].
A relevant point here may be the trend-level positive correlation
between basic processing speed as assessed by trail making A, GH
peak, and radiation dose. This essentially indicates better perfor-
mance with lower GH levels; this is again in contradiction with our
previous study [22], where childhood-onset GHD was associated
with reduced trail making A performance. A related ﬁnding was
reported by Peace et al. [23], who observed that GHD patients who
had received radiation therapy in the past actually performed better
on the trail making A than GHD patients without past radiation expo-
sure, but that these radiation doses may be unfavorable for executive-
function processes. This would explain why low GH was associated
with impairments in interference control and attentional shifting in
the present sample, but not for patients without a history of radiation
therapy, as we reviewed previously [24].
In addition to the relationship between GH secretion and cogni-
tion after cranial radiotherapy, we assessed plasma IGF-I. A relation
between IGF-I and short-term and working memory, as well as with
central motor activation, which possibly differs from the relation
between GH and cognition, was found. These data are in line with
previous observations [15] and suggest a disruption between GH
and IGF-I mediated effects after brain irradiation, similar to the previ-
ously reported effects of aging. The correlation between IGF-I and the
LRP measuring selective motor preparation may be explained by the
supportive effect of IGF-I for the myelin that surrounds the axons,
and may fasten communication between neurons.
In conclusion, the present data on GH secretion and IGF-I, in a
speciﬁc population of subjects exposed to brain irradiation, aremplex ﬁgure test (GHD vs. non-GHD subjects) (a) and signiﬁcant correlation between
Table 2
Neuropsychological assessment and results: correlation with IGF-I, GH peak and group difference (GHD).
Neuropsychological test Putative cognitive function Reference IGF-I GH peak GHD
r; p r; p F; p
Stroop color word task
Word Word reading 1 .15; .54 −.38; .11 4.44; .05
Color Color naming 1 .06; .80 −.25; .30 5.89; .03
Color and word Color naming and interference control 1 .11; .67 −.30; .21 10.64; .01
Color and word minus color Interference control 1 .12; .64 −.28; .25 8.50; .01
Color/color and word Interference control 1 −.15; .53 .14; .58 2.13; .16
Trail making task (TMT)
Trail making task A Processing speed, attention 2/3 .16; .51 .40; .09 1.22; .28
Trail making task B Concept shifting 2/3 −.16; .51 .05; .84 .22; .64
TMT B minus A Planning of movement and cognitive processing speed 4 −.33; .17 −.27; .27 2.41; .14
TMT B/A Attentional shifting 5 −.26; .28 −.37; .12 5.14; .04
Rey–Osterrieth complex ﬁgure test
Immediate recall score Immediate visual memory 3 .32; .18 .43; .06 2.03; .17
Delayed recall score Delayed visual memory 3 .21; .39 .61; .01 3.94; .06
Delayed/immediate recall score Difference between delayed and immediate memory 3 −.50; .03 .64; .00 8.22; .01
Selective attention task
Target detection Sensory discrimination and selective attention 6 −.14; .58 .29; .22 3.94; .06
N2b (ERP) Anterior (Fz) attentional process 6 −.39; .09 −.25; .30 2.17; .16
15 Word test (RAVLT)
Recall score Verbal memory 4 .09; .72 .19; .43 1.27; .27
Immediate recall score Immediate verbal memory 2/3 .02; .94 .15; .53 .29; .60
Delayed recall score Delayed verbal memory 2/3 .21; .38 .31; .19 2.06; .17
Recognition score Recognition memory 3 −.39; .10 .15; .55 .79; .39
Verbal ﬂuency
Letter (N) Language, executive function 3 −.19; .44 .08; .73 1.07; .32
Letter (A) Language, executive function 3 −.24; .32 .03; .91 2.28; .15
Category animal Language, executive function 3 −.02; .94 .05; .83 .98; .34
Brixton Spatial Anticipation Task Spatial learning and working memory 7 −.16; .51 −.10; .69 1.48; .24
Dutch National Adult Reading Test verbal intelligence 2 −.08; .73 .18; .46 1.29; .27
Wechsler Adult Intelligence Scale (WAIS)
Digit symbol substitution Cognitive and perceptual-motor processing speed 4 .01; .96 .15; .55 .46; .51
Similarities Concept formation and abstract reasoning 3 −.19; .44 .16; .51 1.42; .25
Digit span
Span forward Short-term memory 2/3 .42; .07 .62; .01 .89; .36
Span backward Short-term and working memory 2/3 .23; .34 .46; .05 1.04; .32
Span total 2/3 .51; .03 .39; .10 1.12; .31
1—Lansbergen (2007), 2—van Dam et al. (2006), 3—van Zandvoort et al. (2005), 4—Aleman et al. (1999), 5—new measure, 6—Ref. [17], 7—Shallice and Burgess (1996).
Lansbergen, M.M., Kenemans, J.L., van Engeland, H., 2007. Stroop interference and attention-deﬁcit/hyperactivity disorder: a review and meta-analysis. Neuropsychology. 21(2),
251–262.
van Dam, P.S., 2006. Somatotropic therapy and cognitive function in adults with growth hormone deﬁciency: a critical review. Treat Endocrinol. 5 (2), 1.
van Zandvoort, M.J., Kessels, R.P., Nys, G.M., de Haan, E.H., Kappelle L.J., 2005. Early neuropsychological evaluation in patients with ischaemic stroke provides valid information. Clin
Neurol Neurosurg. 107(5), 385–92.
Aleman, A., Verhaar, H.J., De Haan, E.H., De Vries, W.R., Samson, M.M., Drent, M.L., van der Veen, E.A., Koppeschaar, H.P., 1999. Insulin-like growth factor-I and cognitive function in
healthy older men. J. Clin. Endocrinol. Metab. 84, 471–475.
Shallice, T. and Burgess, P. W. (1996) The domain of supervisory processes and the temporal organisation of behaviour. Philosophical Transactions of the Royal Society of London B,
351, 1405–1412.
46 E.H. Quik et al. / Growth Hormone & IGF Research 22 (2012) 42–47consistent with other reports on memory deﬁcits in subjects with
low GH secretion and the association between selective motor activa-
tion and IGF-I. In contrast, reductions in interference control andFig. 4.Mean (±SD) proportion of targets detected (GHD vs. non-GHD subjects) during the s
tical areas (Fz) (b). No signiﬁcant differences between GHD and non-GHD were observed.attentional shifting as observed in the present GHD patients are
quite discrepant from previous reports and may rather reﬂect radia-
tion effects.elective attention task (a) and mean activity area 280–400 ms (N2b) over anterior cor-
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